Start with its own history
At 24.93×, RHHBY is 20.4% above its 10-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.
OTC · RHHBYDrug Manufacturers - GeneralUpdated Nov 4, 2026
Roche Holding AG P/E ratio
Current valuation, historical context, and peer comparisons.
Current P/E ratio
24.93×
20.4% abovethe 10-year annual average
Share price60.95
÷Earnings per share2.4453
Price and EPS in quote currency. Calculation details
Investors are paying 24.93 for every 1 of reported earnings per share.
P/E over time
2016 – 2025
Annual P/ESelected-period average 20.70×
3-year average20.65×3 positive annual observations
5-year average20.75×5 positive annual observations
10-year average20.70×10 positive annual observations
Peer median · TTM36.76×8 peers with positive P/E
Historical P/E ratios
Annual period-end data · 23 observations
| Period end | P/E | Change |
|---|---|---|
| Dec 31, 2025 | 20.28× | -17.8% |
| Dec 31, 2024 | 24.66× | +45.1% |
| Dec 31, 2023 | 16.99× | -9.2% |
| Dec 31, 2022 | 18.71× | -19.1% |
| Dec 31, 2021 | 23.13× | +25.2% |
| Dec 31, 2020 | 18.48× | -7.2% |
| Dec 31, 2019 | 19.91× | +0.6% |
| Dec 31, 2018 | 19.79× | -18.8% |
View all 23 annual observations +
| Period end | P/E | Change |
|---|---|---|
| Dec 31, 2017 | 24.36× | +17.7% |
| Dec 31, 2016 | 20.69× | -22.1% |
| Dec 31, 2015 | 26.55× | +8.1% |
| Dec 31, 2014 | 24.56× | +29.8% |
| Dec 31, 2013 | 18.92× | +14.4% |
| Dec 31, 2012 | 16.55× | +14.4% |
| Dec 31, 2011 | 14.46× | +7.0% |
| Dec 31, 2010 | 13.51× | -31.1% |
| Dec 31, 2009 | 19.61× | +25.9% |
| Dec 31, 2008 | 15.58× | -9.5% |
| Dec 31, 2007 | 17.22× | -27.2% |
| Dec 31, 2006 | 23.65× | -16.0% |
| Dec 31, 2005 | 28.15× | +69.0% |
| Dec 31, 2004 | 16.65× | -51.1% |
| Dec 31, 2003 | 34.08× | N/M |
Change is relative to the preceding observation. N/M values are excluded from averages.
How RHHBY compares
Company P/E vs. peer trailing-12-month ratios
| Company | P/E ratio |
|---|---|
 RHHBY This stockRoche Holding AG | 24.93× |
 AZNAstraZeneca PLC | 26.54× |
 SNYSanofi | 25.72× |
 MRKMerck & Co., Inc. | 153.41× |
 GSKGSK plc | 17.50× |
 PFEPfizer Inc. | 43.56× |
 NVSNovartis AG | 31.62× |
 LLYEli Lilly and Company | 45.90× |
 JNJJohnson & Johnson | 41.89× |
Peers are selected by the data provider. Business models and earnings definitions can differ.
Put the numbers in context
What does RHHBY’s P/E tell you?
Compare like with like
The median of the 8 positive peer ratios above is 36.76×. Check growth, margins, debt, and earnings quality before interpreting the gap. A faster-growing business may justify a higher multiple.
Check what drives earnings
One-off gains can temporarily lower P/E; unusual charges can raise it. Reported earnings and forward estimates answer different questions. Pair this view with return on equity and liquidity for a fuller picture.
Keep your research connected
Take RHHBY into your spreadsheet
Pull historical P/E into Excel or Google Sheets with Wisesheets. Build your own comparisons alongside the rest of your financial model.
Explore WisesheetsQuarterly P/E · latest quarterLQ selects the latest reported quarter. Requires the Wisesheets add-in. See available data
=WISE("RHHBY", "PE Ratio", "LQ")Sources & calculation methodology
Current P/E
Share price 60.95 ÷ EPS 2.4453 = 24.93×. Data is supplied by Financial Modeling Prep through Wisesheets. Quote feed updated Nov 4, 2026; this is not a real-time trading quote.
History & averages
Annual and quarterly P/E observations are provided separately from the current quote. Averages use the latest 3, 5, or 10 annual observations, excluding missing and nonpositive ratios. Pre-IPO observations are omitted. These are period-end observations, not daily averages.
Data definitions and limitations
The current quote feed does not specify the exact EPS filing-period end or whether EPS is basic or diluted. We do not label it as forward P/E. Peer ratios are explicitly trailing-12-month (TTM) values. Historical observations do not include independently verified price and EPS inputs. Sources may update on different schedules; rounded inputs can produce small calculation differences. Historical comparisons describe past pricing, not an estimate of fair value.
RHHBY P/E ratio: common questions
The essentials behind the numbers.
Roche Holding AG's current P/E is 24.93× based on the quote data last updated Nov 4, 2026. It represents the share price divided by reported earnings per share. Prices and earnings may refresh on different schedules.
Annual P/E uses earnings for a completed fiscal year. Trailing-12-month (TTM) P/E uses the latest four quarters, while forward P/E uses forecast earnings. These are not interchangeable. This page labels peer ratios as TTM and shows dated annual or quarterly historical observations; it does not show forward estimates.
N/M means not meaningful: the feed has no positive P/E for that observation. Negative or zero earnings should not be ranked as a low positive valuation multiple. N/M observations are excluded from the averages shown above.
Divide the share price by earnings per share (EPS). For example, a share price of 100 and EPS of 5 gives a P/E of 20×. This page uses the price and EPS supplied together in the quote when both are positive.
Price timestamps, EPS definitions, share classes, adjustments, and fiscal periods can differ. A forward P/E also uses forecast earnings rather than reported earnings. Compare the inputs and as-of dates before comparing two displayed ratios.
Not necessarily. The average describes previous market pricing, not fair value. Changes in earnings quality, growth expectations, debt, accounting, and business risk can justify a different multiple today.